News & Updates

In patients with poor asthma control, switching from fluticasone propionate (FP) monotherapy to inhaled corticosteroid (ICS) plus a long-acting beta-agonist (LABA) combination therapy may help improve symptom control and reduce the use of reliever or rescue medications, according to a study.

Initiation of venetoclax for acute myeloid leukaemia (AML) in the outpatient setting with a pharmacist-led interdisciplinary protocol is both feasible and safe, reports a study.

Results of nintedanib use in patients with early-stage idiopathic pulmonary fibrosis (IPF) show a stable change in forced vital capacity (FVC) and a gradual decline in diffusing capacity of the lungs for carbon monoxide (DLCO) at week 52, according to an ongoing study presented at APSR 2023. In addition, treatment discontinuation is comparable to that in previous clinical trials.

In a substudy of a phase II obesity trial, individuals with MASLD* and obesity benefited significantly from retatrutide, a once-weekly, injectable, novel synthetic molecule that has shown potent agonist action at GIP**, GLP-1***, and glucagon receptors.